Bayern Nordic has been awarded a $63 million contract by the U.S. government to produce additional bulk product and finished lyophilized doses of the JYNNEOS smallpox/mpox vaccine.
The order, received from the U.S. Biomedical Advanced Research and Development Authority, is intended to replenish bulk product inventories and support the production of one million doses of the vaccine.
Bulk products, which account for the majority of the contract value, are essential to replenish depleted stocks during the 2022 MPOX outbreak response.
The replenishment is essential to meet the terms of Bayern Nordic’s existing contracts, including the supply of freeze-dried vaccine for the US smallpox program.
The contract will allow the production of 1 million doses of freeze-dried vaccine using part of the company’s large inventory.
The bulk of the vaccine is expected to be manufactured in 2025, but deliveries of the freeze-dried vaccine are scheduled for 2026, keeping in mind international orders to combat the ongoing MPOX epidemic.
Paul Chaplin, President and CEO of Bayern Nordic, said: “This award further strengthens our public protection business portfolio beyond 2025 and once again represents strong endorsement of MVA-BN as a leader in smallpox and multiple sclerosis vaccines.”
“The current smallpox outbreak is a reminder of how vulnerable the global community is to infectious diseases, but we remain committed to supporting all governments and organizations to ensure equitable access to variola/smallpox vaccines during the current public health emergency and beyond.”
The modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) nonreplicating mpox vaccine, marketed as JYNNEO, has been approved in Canada, the European Union, Mexico, Singapore, Switzerland, the United Kingdom, and the United States.
MVA-BN was originally developed as a smallpox vaccine in partnership with the U.S. government and was designed to ensure adequate vaccine supply for the entire population, including those who are immunocompromised and not recommended to receive the traditional replicating smallpox vaccine.
This latest development comes after the European Medicines Agency (EMA) approved Bayer Nordic’s mpox vaccine for use in adolescents, raising the possibility of its use in this age group in Africa.
The Global Alliance for Vaccines and Immunisation recently signed an advance purchase agreement with Bayer Nordic AG to secure 500,000 doses of the mpox vaccine.
“Bavarian Nordic Wins Additional MPOX Vaccine Contract in US” was originally produced and published by Pharmaceutical Technology, a brand owned by GlobalData.
The story continues
The information on this site is published in good faith for general information purposes only. It is not intended to amount to advice on which you should rely and we make no representations, warranties or guarantees, express or implied, as to its accuracy or completeness. You should always obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on this site.
